STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

STAT PlusBiotech At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways This is STAT’s ASCO in 30 Seconds newsletter Manage alerts for this article Email this article Share this article By Adam Feuerstein, Matthew Herper, Angus Chen, and Katherine MacPhailJune 1, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.Angus Chen[email protected]Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.Katherine MacPhail[email protected]Katherine MacPhail is a reporter and editorial events programmer for STAT. We asked Brian Wolpin, the presenter for yesterday’s plenary on the daraxonrasib pancreatic cancer study, about the sustained standing ovation that interrupted his remarks. “Honestly, it was tough to hold it together in that moment and then keep going. It felt like 20 years of work all rolled into 12 minutes,” he told us.Advertisement It was a truly memorable ASCO meeting. With this newsletter, we say goodbye from Chicago. Thanks again for spending time with us. You can still join our virtual recap on Wednesday! STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In ASCO, Cancer, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils. Angus Chen Cancer Reporter Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. Katherine MacPhail Reporter, Live Journalism Katherine MacPhail is a reporter and editorial events programmer for STAT. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout June 1, 2026 STAT Plus: A turning point for pancreatic cancer patients Biotech June 1, 2026 STAT Plus: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug Advertisement Biotech May 31, 2026 STAT Plus: A standing ovation for RevMed, and caution for Akeso Pharma May 31, 2026 Ultra-low doses could bring costly cancer treatments to more patients in poorer countries Biotech May 31, 2026 STAT Plus: Practice-changing results reported for Revolution Medicines pancreatic cancer drug Subscriber Picks